Remaining Unmet Needs and Emerging Therapies in PTCL

Brammer and Zinzani close by surveying persistent unmet needs and the therapies on the horizon for peripheral T-cell lymphoma. They discuss the cautious history of checkpoint inhibition in T-cell disease, including reports of hyperprogression and the unusual biology in which programmed cell death protein 1 can behave as a tumor suppressor, while noting that combination approaches have shown more encouraging early signals. The experts review emerging cellular and antibody strategies, including CAR T-cell programs directed at CD5 and CD94, ongoing efforts in cutaneous and cytotoxic subtypes, and T-cell receptor–directed approaches targeting TRBC1 and TRBC2. They acknowledge that bispecific antibody development has so far yielded limited results in this setting. Both temper optimism with realism, observing that several of these approaches remain years from maturity, and they reaffirm duvelisib's near-term role in opening the door to durable remissions and potentially curative transplant before offering their closing remarks.